REPROVA

Prostate cancer screening has suddenly become one of the most talked about – and misunderstood – topics in healthcare. The UK’s National Screening Committee (UKNSC) has recommended against offering routine PSA tests to all men, even though prostate cancer is one of the most commonly diagnosed cancers in the country.

At the same time, the huge new TRANSFORM trial has just launched, a study that is aiming to  redesign prostate cancer screening using genetics, MRI, and smarter, risk-based testing rather than a “one-size-fits-all” screening approach.

If you’ve ever wondered why men’s reproductive health feels like an afterthought, this moment explains a lot…

Let’s start with the groundwork: 

The prostate is a small gland that helps produce seminal fluid, and most of the time, it quietly gets on with its job. Prostate cancer starts when cells inside this gland begin to grow uncontrollably, mainly affecting men aged around 50-70. Sometimes this happens so slowly that it may never cause a problem at all! Other times, the cancer is aggressive and spreads quickly. And that contrast, harmless vs dangerous, is exactly what makes screening so  complicated.

Right now, the UK has no national routine screening programme. But men over 50 can request a PSA blood test through their GP, but it’s not automatically offered.

But here’s the catch, a high PSA doesn’t always mean cancer (infections, inflammation and even recent exercise can raise it), and a normal PSA doesn’t always rule cancer out.

This uncertainty is exactly why the UKNSC is hesitant. PSA testing can lead to unnecessary biopsies, finding cancers that would never cause harm, overtreatment, and long-term side effects

All of this can create avoidable stress, both physical and mental for men, and strain NHS resources. So, while PSA testing can save lives, it can also cause avoidable harm. And that’s the core issue.

Well, most men don’t have symptoms in the early stages of prostate cancer. By the time symptoms appear, the disease is usually more advanced, which limits treatment options and reduces survival. Early detection genuinely saves lives!

But the tools we currently have aren’t reliable enough to screen everyone fairly and safely. That’s why this moment, and trials like TRANSFORM, are so important.

As part of my degree, my honours project was on neuroendocrine prostate cancer (NEPC), one of the most aggressive and confusing forms of the disease. I spent months trying to understand how a typical prostate cancer cell can suddenly change into a completely different cell type, one that behaves more like the neuroendocrine cells we usually see in the brain and nervous system. The shifting of cell types makes the disease much harder to treat. It almost felt like the cancer was breaking its own rules!

My project focused on whether there are signals or genetic triggers that cause this change, and whether they could one day be targeted with treatment. Because the more we understand why this shift happens, the better chance we have of stopping it.

And while I loved digging into the science, I’m also an aspiring medic, so I’m always thinking about how this research actually affects real patients. That’s why the current PSA screening debate matters so much to me.

Better screening doesn’t just change statistics… it changes people’s futures.

The committee believes we still don’t have enough evidence that mass PSA screening would save more lives than it harms.

Their reasoning:

• PSA can be high for reasons other than cancer.
• PSA screening can pick up harmless cancers that never needed treatment.
• Overdiagnosis: unnecessary biopsies and lifelong side effects.

Really, they only recommended screening for men with BRCA1/2 variants (a well defined high-risk group). 

But here’s the part that worries me. This decision still leaves out high-risk groups like Black men and men with a strong family history. And that is where the silence around men’s reproductive health becomes deathly loud. If we already know that certain men are at higher risk, why isn’t screening tailored to them? Here enters TRANSFORM. 

TRANSFORM is the UK’s biggest prostate-screening study in 20 years! It will test combinations of PSA, genetic risk scores, and fast MRI. 

Its goal is simple: find a screening method that catches dangerous cancers early without causing unnecessary harm. But here’s the problem…

TRANSFORM will take about two years before it starts giving us meaningful answers, which sounds fine until you realise something important: high-risk men exist right now.

Black men, men with a strong family history, men with past concerning PSA results… none of them are offered routine screening while we wait for TRANSFORM’s data.

And this is where my frustration (and honestly, confusion) kicks in. If we already know these groups carry a higher risk, why isn’t there a temporary, targeted screening pathway while the UK waits for better evidence? This isn’t about mass screening, it’s about evidence-based prioritisation, something we use in so many other areas of medicine. So why not here too?

Rightfully so, Prostate Cancer UK called the decision deeply disappointing, especially for the communities already at highest risk. Their position is clear: we need screening, we need it now. And honestly? I agree. Really, TRANSFORM might finally deliver the evidence required.

We’re closer than ever to screening that’s personalised, safer, and genuinely life-saving.

If we’re redesigning prostate cancer screening from scratch, why not redesign men’s reproductive health care at the same time? Why stop at cancer? Why not build better systems for hormone health, fertility issues, early detection, and try placing more focus on prevention? 

If we’re debating whether men should have a national screening programme, it does makes me wonder, why is there still no screening test at all for endometriosis? Let’s talk about that next week. 

REPROVA.